MRT68921: ULK1 Kinase Inhibition for Autophagy Research

Executive Summary: MRT68921 is a dual autophagy kinase ULK1/2 inhibitor with nanomolar potency (IC50 for ULK1: 2.9 nM; ULK2: 1.1 nM) (source: product_spec). It blocks autophagy initiation by inhibiting ULK1-mediated ATG13 phosphorylation, reducing LC3 flux in wild-type but not mutant ULK1 (M92T) cells (source: DOI). MRT68921 shows >80% inhibition of TBK1/IKK and AMPK-related kinases but does not depend on these for its main autophagy-blocking effect (source: product_spec). The compound is supplied as a hydrochloride salt for research use only and should be stored at -20°C (source: product_spec). No in vivo or clinical data are available; its use is restricted to preclinical laboratory settings.

Biological Rationale

Autophagy is a conserved eukaryotic process essential for degrading misfolded proteins, damaged organelles, and lipid droplets, thereby maintaining cellular homeostasis (source: DOI). The process involves ULK1 kinase, which phosphorylates ATG13 to initiate autophagosome formation. Dysregulation of autophagy is implicated in lipotoxicity, metabolic disorders, and inflammation due to lipid accumulation and impaired organelle clearance (source: DOI). In mammalian and model fish cells, autophagy regulates lipid metabolism, and targeted inhibition of ULK1 provides a mechanistic tool to dissect these pathways. APExBIO’s MRT68921 enables researchers to temporally and biochemically block autophagy at its initiation step, facilitating studies in systems ranging from cultured mammalian cells to non-model vertebrates.

Mechanism of Action of MRT68921 dual autophagy kinase ULK1/2 inhibitor

MRT68921 acts as a highly selective, dual inhibitor of ULK1 and ULK2, both of which are serine/threonine kinases essential for autophagy initiation (source: product_spec). By binding to the ATP-binding pocket of these kinases, MRT68921 prevents phosphorylation of ATG13, an early step in autophagosome biogenesis (source: DOI). In cellular assays, this leads to a reduction in LC3-II formation and autophagic flux, specifically in cells expressing wild-type ULK1 but not M92T mutants (source: product_spec). While MRT68921 can inhibit other kinases such as TBK1/IKK and AMPK-related kinases (>80% inhibition), these do not account for its autophagy inhibitory effect, as shown by pathway dissection studies (source: product_spec).

Evidence & Benchmarks

• MRT68921 exhibits IC50 values of 2.9 nM for ULK1 and 1.1 nM for ULK2 in biochemical assays (source: product_spec).
• In cell-based studies, MRT68921 blocks ATG13 phosphorylation and reduces LC3 flux in wild-type but not M92T mutant ULK1 cells (source: DOI).
• The compound does not block autophagy by inhibiting TBK1/IKK or AMPK kinases, as these are not required for its autophagy-blocking effect (source: product_spec).
• Autophagy inhibition with MRT68921 provides a research tool for dissecting lipid metabolism and lipotoxicity in vertebrate cells (source: DOI).
• No in vivo efficacy or toxicity data for MRT68921 are currently available; its use is limited to preclinical, in vitro contexts (source: product_spec).

This article extends the analysis in Harnessing MRT68921 for Strategic Autophagy Inhibition by focusing on evidence-backed workflow parameters and explicitly defining compound boundaries for preclinical use. It also updates MRT68921: Dissecting Autophagy Inhibition for Lipid Metabolism by integrating recent findings on ATG13 phosphorylation blockade and mechanistic specificity. For a comprehensive troubleshooting guide, see MRT68921: A Precision Dual ULK1/2 Inhibitor for Advanced Research, which is complemented here by strict evidence labeling and protocol clarity.

Applications, Limits & Misconceptions

MRT68921 is intended solely for research use in dissecting the autophagy signaling pathway, especially for mechanistic studies of autophagy initiation, lipid metabolism, and disease modeling in vitro. Its use is not validated for diagnostic or therapeutic applications. As a selective ULK1 kinase inhibitor, it is best applied in cell-based assays where fine temporal control of autophagy is required.

Common Pitfalls or Misconceptions

• Not water/ethanol soluble: MRT68921 is insoluble in water and ethanol; DMSO is required for solution preparation (≥2.18 mg/mL with warming/sonication) (source: product_spec).
• No in vivo/clinical data: There are no animal or human studies; use is restricted to preclinical laboratory experiments (source: product_spec).
• Not suitable for diagnostic/medical use: MRT68921 is a research use only ULK1 inhibitor and not intended for clinical interventions (source: product_spec).
• Off-target kinase activity: While it inhibits TBK1/IKK and AMPK-related kinases (>80%), autophagy blockade is specific to ULK1/2 inhibition in current models (source: product_spec).
• ATG13 phosphorylation/LC3 flux as primary readouts: Do not infer autophagy inhibition solely by changes in general protein phosphorylation; use specific markers (source: DOI).

Workflow Integration & Parameters

Protocol Parameters

• Kinase inhibition assay | IC50: 2.9 nM (ULK1), 1.1 nM (ULK2) | in vitro biochemical | Defines compound potency and selectivity | product_spec
• Cell-based autophagy assay | 100–500 nM MRT68921 | mammalian and fish cell lines | Empirically determined window for effective ATG13/LC3 modulation | workflow_recommendation
• Solubility | ≥2.18 mg/mL in DMSO (with warming/sonication) | solution prep | Ensures correct stock preparation and dosing | product_spec
• Storage temperature | -20°C | stock and working solution | Maintains compound stability for short-term use | product_spec
• Autophagic flux measurement | LC3-II/LC3-I ratio, ATG13 phosphorylation | cell-based | Primary indicators of autophagy inhibition | DOI

Conclusion & Outlook

MRT68921, provided by APExBIO, is a potent, dual ULK1/2 inhibitor enabling fine control of autophagy initiation in preclinical research. Its nanomolar efficacy, pathway specificity, and workflow clarity make it the standard for dissecting autophagy signaling and lipid metabolism in vitro. However, its use is currently limited to cell-based studies, with no in vivo or clinical validation. Future developments should focus on expanding its validated applications and benchmarking against emerging autophagy modulators, strictly within the boundaries set by current evidence (source: DOI).